Johnson & Johnson Submits Supplemental Biologics License Application to the FDA for Tremfya in Ulcerative Colitis Treatment

Submission is based on positive results from the company’s Phase III QUASAR clinical trial, in which Tremfya (guselkumab) produced positive results treating moderately to severely active ulcerative colitis.

Source link
#Johnson #amp #Johnson #Submits #Supplemental #Biologics #License #Application #FDA #Tremfya #Ulcerative #Colitis #Treatment